Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma-Pharma Announces Submission for Their Botulinum Toxin to Treat Glabellar (frown) Lines to the German Authority BfArM","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"AUSTRIA","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"China National Biotech Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Croma Establishes New Joint Venture in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma-Pharma Announces Enrollment of First Patient in Hyaluronic Acid Dermal Filler Clinical Trial in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Croma-Pharma

    Menu

    Croma-Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Croma-Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Croma-Pharma Announces Enrollment of First Patient in Hyaluronic Acid Dermal Filler Clinical Trial in China

              Details:

              Princess Volume Plus (hyaluronic acid) dermal filler and Lidocaine with the intention to confirm the efficacy and safety in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants.

              Lead Product(s): Hyaluronic Acid,Lidocaine

              Therapeutic Area: Dermatology Product Name: Princess Volume Plus

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Croma-Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®

              Details:

              Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other milestone payments.

              Lead Product(s): Lidocaine,Tetracaine

              Therapeutic Area: Neurology Product Name: Pliaglis

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Crescita Therapeutics

              Deal Size: $1.4 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Croma-Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Croma Establishes New Joint Venture in China

              Details:

              The joint venture comprises Croma's Hyaluronic Acid Filler Princess® VOLUME and additional filler and facial aesthetic products and CNBG's multi-channel distribution, marketing experience and synergistic products, specifically its botulinum toxin product Heng Li®.

              Lead Product(s): Hyaluronic Acid

              Therapeutic Area: Dermatology Product Name: Hyaluronic Acid Filler Princess

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: China National Biotech Group

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Croma-Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Croma-Pharma Announces Submission for Their Botulinum Toxin to Treat Glabellar (frown) Lines to the German Authority BfArM

              Details:

              Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.

              Lead Product(s): Botulinum toxin type A

              Therapeutic Area: Dermatology Product Name: BoNT/A-DP

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY